Genetic alterations in anaplastic thyroid carcinoma and targeted therapies (Review)
- Authors:
- Zongjuan Li
- Yang Zhang
- Ruonan Wang
- Kun Zou
- Lijuan Zou
-
Affiliations: Department of Radiation Oncology, The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning 116027, P.R. China, Department of Radiation Oncology, Yantai Yuhuangding Hospital Affiliated to Qingdao University Medical College, Yantai, Shandong 264000, P.R. China, Department of Radiation Oncology, The First Affiliated Hospital, Dalian Medical University, Dalian, Liaoning 116011, P.R. China - Published online on: August 8, 2019 https://doi.org/10.3892/etm.2019.7869
- Pages: 2369-2377
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
O'Neill JP and Shaha AR: Anaplastic thyroid cancer. Oral Oncol. 49:702–706. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jin S, Borkhuu O, Bao W and Yang YT: Signaling pathways in thyroid cancer and their therapeutic implications. J Clin Med Res. 8:284–296. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu KT, Yu XM, Audhya AW, Jaume JC, Lloyd RV, Miyamoto S, Prolla TA and Chen H: Novel approaches in anaplastic thyroid cancer therapy. Oncologist. 19:1148–1155. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Keutgen XM, Sadowski SM and Kebebew E: Management of anaplastic thyroid cancer. Gland Surg. 4:44–51. 2015.PubMed/NCBI | |
|
Saini S, Maker AV, Burman KD and Prabhakar BS: Genetic aberrations and alterations in signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer. Biochim Biophys Acta Rev Cancer. 2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Guerra A, Di Crescenzo V, Garzi A, Cinelli M, Carlomagno C, Tonacchera M, Zeppa P and Vitale M: Genetic mutations in the treatment of anaplastic thyroid cancer: A systematic review. BMC Surg. 13 (Suppl 2):S442013. View Article : Google Scholar : PubMed/NCBI | |
|
Xu B and Ghossein R: Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma. Endocr Pathol. 27:205–212. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Perri F, Pezzullo L, Chiofalo MG, Lastoria S, Di Gennaro F, Scarpati GD and Caponigro F: Targeted therapy: A new hope for thyroid carcinomas. Crit Rev Oncol Hematol. 94:55–63. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bartholomeusz C and Gonzalez-Angulo AM: Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:121–130. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Saji M and Ringel MD: The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 321:20–28. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P and Bouscary D: PI3K and mTOR signaling pathways in cancer: New data on targeted therapies. Curr Oncol Rep. 14:129–138. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cao F, Zhang C, Han W, Gao XJ, Ma J, Hu YW, Gu X, Ding HZ, Zhu LX and Liu Q: p-Akt as a potential poor prognostic factor for gastric cancer: A systematic review and meta-analysis. Oncotarget. 8:59878–59888. 2017.PubMed/NCBI | |
|
Phyu SM and Smith TAD: Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: Effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation. Invest New Drugs. 37:424–430. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xing M: Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid. 20:697–706. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, Rubinstein JC, Choi M, Kiss N, Nelson-Williams C, et al: Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet. 24:2318–2329. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, et al: Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 126:1052–1066. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, et al: Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 11:317–328. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sirohi B, Rastogi S and Dawood S: Buparlisib in breast cancer. Future Oncol. 11:1463–1470. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Xu X, Li Y, Zou K, Zhang Z, Xu X, Liao Y, Zhao X, Jiang W, Yu W, et al: Synergistic antitumor effect of BKM120 with prima-1met via inhibiting PI3K/AKT/mTOR and CPSF4/hTERT signaling and reactivating mutant P53. Cell Physiol Biochem. 45:1772–1786. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH and Li Y: Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 4:e8752013. View Article : Google Scholar : PubMed/NCBI | |
|
Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH and Li Y: PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis. 5:e14372014. View Article : Google Scholar : PubMed/NCBI | |
|
Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, Aimone P, Fretault N, Dharan B, Tavorath R and Hirawat S: PI3K inhibitors as new cancer therapeutics: Implications for clinical trial design. Onco Targets Ther. 9:203–210. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Saran U, Foti M and Dufour JF: Cellular and molecular effects of the mTOR inhibitor everolimus. Clin Sci (Lond). 129:895–914. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H, Roozen IC, Bos M, Corver WE, van Wezel T, et al: Everolimus in patients with advanced follicular-derived thyroid cancer: Results of a phase II clinical trial. J Clin Endocrinol Metab. 102:698–707. 2017.PubMed/NCBI | |
|
Onoda N, Nakamura M, Aomatsu N, Noda S, Kashiwagi S, Kurata K, Uchino S and Hirakawa K: Significant cytostatic effect of everolimus on a gefitinib-resistant anaplastic thyroid cancer cell line harboring PI3KCA gene mutation. Mol Clin Oncol. 3:522–526. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yi H, Ye X, Long B, Ye T, Zhang L, Yan F, Yang Y and Li L: Inhibition of the AKT/mTOR pathway augments the anticancer effects of sorafenib in thyroid cancer. Cancer Biother Radiopharm. 32:176–183. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lin SF, Huang YY, Lin JD, Chou TC, Hsueh C and Wong RJ: Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS One. 7:e467262012. View Article : Google Scholar : PubMed/NCBI | |
|
Petrulea MS, Plantinga TS, Smit JW, Georgescu CE and Netea-Maier RT: PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma. Cancer Treat Rev. 41:707–713. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, Fenga C, Spandidos DΑ, Libra M and Tsatsakis AM: Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). Int J Oncol. 48:869–885. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R, Liu D, Trink E, Bojdani E, Ning G and Xing M: The akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab. 96:E577–E585. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pflaum J, Schlosser S and Muller M: P53 family and cellular stress responses in cancer. Front Oncol. 4:2852014. View Article : Google Scholar : PubMed/NCBI | |
|
Parrales A and Iwakuma T: Targeting oncogenic mutant p53 for cancer therapy. Front Oncol. 5:2882015. View Article : Google Scholar : PubMed/NCBI | |
|
Maslon MM and Hupp TR: Drug discovery and mutant p53. Trends Cell Biol. 20:542–555. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bullock AN and Fersht AR: Rescuing the function of mutant p53. Nat Rev Cancer. 1:68–76. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Wiman KG: Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 13:921–926. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A and Reid TR: Going viral: A review of replication-selective oncolytic adenoviruses. Oncotarget. 6:19976–19989. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, Sloan JA, Atherton P, Edmonson JH, Erlichman C, et al: Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 12:437–445. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Makower D, Rozenblit A, Kaufman H, Edelman M, Lane ME, Zwiebel J, Haynes H and Wadler S: Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res. 9:693–702. 2003.PubMed/NCBI | |
|
Chen GX, Zhang S, He XH, Liu SY, Ma C and Zou XP: Clinical utility of recombinant adenoviral human p53 gene therapy: Current perspectives. Onco Targets Ther. 7:1901–1909. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Pan J, Zhu X, Su Y, Bao L, Qiu S, Zou C, Cai Y, Wu J and Tham IW: Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation. Chin J Cancer Res. 25:715–721. 2013.PubMed/NCBI | |
|
Wade M, Li YC and Wahl GM: MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Oren M, Tal P and Rotter V: Targeting mutant p53 for cancer therapy. Aging (Albany NY). 8:1159–1160. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Selivanova G: Wild type p53 reactivation: From lab bench to clinic. FEBS Lett. 588:2628–2638. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Urso L, Calabrese F, Favaretto A, Conte P and Pasello G: Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. Crit Rev Oncol Hematol. 97:220–230. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, Givol D and D'Orazi G: Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle. 10:1679–1689. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bykov VJ and Wiman KG: Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett. 588:2622–2627. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Messina RL, Sanfilippo M, Vella V, Pandini G, Vigneri P, Nicolosi ML, Gianì F, Vigneri R and Frasca F: Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. Int J Cancer. 130:2259–2270. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr-Relat Cancer. 20:603–610. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, et al: TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 99:E754–E765. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R and Xing M: TERT promoter mutations in thyroid cancer. Endocr-Relat Cancer. 23:R143–R155. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jin A, Xu J and Wang Y: The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer. Medicine (Baltimore). 97:e115482018. View Article : Google Scholar : PubMed/NCBI | |
|
Dong H, Shen WZ, Yan YJ, Yi JL and Zhang L: Effects of BRAF(V600E) mutation on Na(+)/I(−) symporter expression in papillary thyroid carcinoma. J Huazhong Uni Sci Technolog. Med Sci. 36:77–81. 2016. | |
|
Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X, Sun H, Shan Z, Wang E, Luo Y, et al: Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab. 100:E632–E637. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Charles RP, Silva J, Iezza G, Phillips WA and McMahon M: Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res. 12:979–986. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W: BRAF inhibitors: The current and the future. Curr Opin Pharmacol. 23:68–73. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ and Sherman SI: Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 23:1277–1283. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI and Sherman EJ: Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: A non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 17:1272–1282. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Marten KA and Gudena VK: Use of vemurafenib in anaplastic thyroid carcinoma: A case report. Cancer Biol Ther. 16:1430–1433. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S and Falchook G: BRAF inhibitors: Experience in thyroid cancer and general review of toxicity. Horm Cancer. 6:21–36. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lim AM, Taylor GR, Fellowes A, Cameron L, Lee B, Hicks RJ, McArthur GA, Angel C, Solomon B and Rischin D: BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma. J Natl Compr Canc Netw. 14:249–254. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Maggisano V, Celano M, Lombardo GE, Lepore SM, Sponziello M, Rosignolo F, Verrienti A, Baldan F, Puxeddu E, Durante C, et al: Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. Mol Cell Endocrinol. 448:34–40. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bu R, Siraj AK, Divya SP, Kong Y, Parvathareddy SK, Al-Rasheed M, Al-Obaisi KAS, Victoria IG, Al-Sobhi SS, Al-Dawish M, et al: Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in middle eastern papillary thyroid cancer. Int J Cancer. 142:2028–2039. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Namba H, Saenko V and Yamashita S: Nuclear factor-kB in thyroid carcinogenesis and progression: A novel therapeutic target for advanced thyroid cancer. Arq Bras Endocrinol Metabol. 51:843–851. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu W, He S, Li Y, Qiu P, Shu M, Ou Y, Zhou Y, Leng T, Xie J, Zheng X, et al: Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells. Vascul Pharmacol. 52:46–54. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sastre-Perona A and Santisteban P: Wnt-independent role of β-catenin in thyroid cell proliferation and differentiation. Mol Endocrinol. 28:681–695. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Shao YY and Ballock RT: Thyroid hormone interacts with the Wnt/beta-catenin signaling pathway in the terminal differentiation of growth plate chondrocytes. J Bone Miner Res. 22:1988–1995. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ito Y, Onoda N, Ito KI, Sugitani I, Takahashi S, Yamaguchi I, Kabu K and Tsukada K: Sorafenib in japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid. 27:1142–1148. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ and Brose MS: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 26:4714–4719. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, et al: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 27:1675–1684. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, Karlin NJ, Traynor AM, Kumar P, Goh BC, et al: A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 97:3179–3184. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, et al: A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 15:717–726. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sasanakietkul T, Murtha TD, Javid M, Korah R and Carling T: Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer. Mol Cell Endocrinol. 469:23–37. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Celano M, Mio C, Sponziello M, Verrienti A, Bulotta S, Durante C, Damante G and Russo D: Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer. Mol Cell Endocrinol. 469:38–47. 2018. View Article : Google Scholar : PubMed/NCBI |
